Anne Murati

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

Limited Prognostic Value of ELN Classification and Relevance of Molecular Ontogeny in Acute Myeloid Leukemia post Myeloproliferative Neoplasms: A Retrospective Multicenter Study.

Limited Prognostic Value of ELN Classification and Relevance of Molecular Ontogeny in Acute Myeloid Leukemia post Myeloproliferative Neoplasms: A Retrospective Multicenter Study.

Journal: Acta haematologica
Published: February 27, 2026

Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis.

Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis.

Journal: Leukemia
Published: March 24, 2025

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.

Journal: Leukemia
Published: October 31, 2024

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Journal: European journal of haematology
Published: April 03, 2024

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.

Journal: American journal of hematology
Published: November 10, 2023

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Journal: European journal of haematology
Published: August 03, 2023

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Journal: Blood advances
Published: September 18, 2020

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Journal: Blood advances
Published: May 12, 2020

Gains of EPOR and ERG genes in adult erythroleukaemia.

Gains of EPOR and ERG genes in adult erythroleukaemia.

Journal: British journal of haematology
Published: April 01, 2020

Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.

Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.

Journal: Haematologica
Published: October 12, 2019

Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.

Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.

Journal: British journal of haematology
Published: July 19, 2019

Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Journal: Genes, chromosomes & cancer
Published: January 28, 2019
Showing 1-12 of 33

Last Updated: 09/26/2026